These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2682 related items for PubMed ID: 20089952

  • 41. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
    Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J.
    Mult Scler; 2012 Sep; 18(9):1269-77. PubMed ID: 22354739
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 46. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators.
    Lancet; 2016 Mar 12; 387(10023):1075-1084. PubMed ID: 26827074
    [Abstract] [Full Text] [Related]

  • 47. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
    Sanford M.
    Drugs; 2014 Aug 12; 74(12):1411-33. PubMed ID: 25063048
    [Abstract] [Full Text] [Related]

  • 48. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD, Jones DE, Goldman MD.
    Expert Opin Drug Saf; 2014 Jul 12; 13(7):989-98. PubMed ID: 24935480
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Treating multiple sclerosis with fingolimod or intramuscular interferon.
    Pozzilli C, Prosperini L, Borriello G.
    Expert Opin Pharmacother; 2010 Aug 12; 11(11):1957-60. PubMed ID: 20426705
    [Abstract] [Full Text] [Related]

  • 52. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
    Doggrell SA.
    Expert Opin Pharmacother; 2010 Jul 12; 11(10):1777-81. PubMed ID: 20408749
    [Abstract] [Full Text] [Related]

  • 53. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 12; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 54. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ.
    CNS Drugs; 2011 Aug 12; 25(8):673-98. PubMed ID: 21790210
    [Abstract] [Full Text] [Related]

  • 55. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov 12; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 56. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb 12; 50(2):18-20. PubMed ID: 22329953
    [Abstract] [Full Text] [Related]

  • 57. [Fingolimod treatment in multiple sclerosis].
    Tanaka M.
    Nihon Rinsho; 2014 Nov 12; 72(11):2010-4. PubMed ID: 25518386
    [Abstract] [Full Text] [Related]

  • 58. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S.
    Drugs Today (Barc); 2010 May 12; 46(5):315-25. PubMed ID: 20517533
    [Abstract] [Full Text] [Related]

  • 59. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 May 12; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 60. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 135.